These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 32450889)

  • 1. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
    Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
    Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.
    Halappanavar S; Nymark P; Krug HF; Clift MJD; Rothen-Rutishauser B; Vogel U
    Small; 2021 Apr; 17(15):e2007628. PubMed ID: 33559363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
    Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
    ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
    Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
    ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary hazard identifications of Graphene family nanomaterials: Adverse outcome pathways framework based on toxicity mechanisms.
    Ding X; Pu Y; Tang M; Zhang T
    Sci Total Environ; 2023 Jan; 857(Pt 1):159329. PubMed ID: 36216050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of AOP networks for reproductive and developmental toxicity assay development.
    Knapen D; Vergauwen L; Villeneuve DL; Ankley GT
    Reprod Toxicol; 2015 Aug; 56():52-5. PubMed ID: 25889759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Adverse Outcome Pathways and Current Applications on Nanomaterials.
    Rolo D; Tavares A; Vital N; Silva MJ; Louro H
    Adv Exp Med Biol; 2022; 1357():415-439. PubMed ID: 35583654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays.
    Sachana M; Willett C; Pistollato F; Bal-Price A
    Reprod Toxicol; 2021 Aug; 103():159-170. PubMed ID: 34147625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.
    Vinken M
    Methods Mol Biol; 2016; 1425():325-37. PubMed ID: 27311472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways.
    Rycroft TE; Foran CM; Thrash A; Cegan JC; Zollinger R; Linkov I; Perkins EJ; Garcia-Reyero N
    ALTEX; 2020; 37(1):64-74. PubMed ID: 31453632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-level overview of the OECD AOP Development Programme.
    Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways.
    Clerbaux LA; Filipovska J; Nymark P; Chauhan V; Sewald K; Alb M; Sachana M; Beronius A; Amorim MJ; Wittwehr C
    ALTEX; 2024; 41(2):233-247. PubMed ID: 37980615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse outcome pathway: a path toward better data consolidation and global co-ordination of radiation research.
    Chauhan V; Beaton D; Hamada N; Wilkins R; Burtt J; Leblanc J; Cool D; Garnier-Laplace J; Laurier D; Le Y; Yamada Y; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1694-1703. PubMed ID: 34919011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.
    Arnesdotter E; Gijbels E; Dos Santos Rodrigues B; Vilas-Boas V; Vinken M
    Methods Mol Biol; 2022; 2425():521-535. PubMed ID: 35188645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicogenomics Data for Chemical Safety Assessment and Development of New Approach Methodologies: An Adverse Outcome Pathway-Based Approach.
    Saarimäki LA; Morikka J; Pavel A; Korpilähde S; Del Giudice G; Federico A; Fratello M; Serra A; Greco D
    Adv Sci (Weinh); 2023 Jan; 10(2):e2203984. PubMed ID: 36479815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials.
    Martens M; Verbruggen T; Nymark P; Grafström R; Burgoon LD; Aladjov H; Torres Andón F; Evelo CT; Willighagen EL
    Front Genet; 2018; 9():661. PubMed ID: 30622555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert consultation is vital for adverse outcome pathway development: a case example of cardiovascular effects of ionizing radiation.
    Chauhan V; Hamada N; Monceau V; Ebrahimian T; Adam N; Wilkins RC; Sebastian S; Patel ZS; Huff JL; Simonetto C; Iwasaki T; Kaiser JC; Salomaa S; Moertl S; Azimzadeh O
    Int J Radiat Biol; 2021; 97(11):1516-1525. PubMed ID: 34402738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.